Floxoptho DF Eye Drops
Floxoptho DF Eye Drops
Composition: Difluprednate 0.05% w/v + Moxifloxacin 0.5% w/v
Formulation: Eye Drops
Category: Antibiotic + Corticosteroid
Packaging: 10ML
Eye Care Focus
Trusted Eye Solutions
Quality Eye Products
Floxoptho DF Eye Drops
Description
Therapy/Class: Antibiotic + Corticosteroid
Mechanism of Action:
Difluprednate: A difluorinated synthetic corticosteroid derivative (butyrate ester) demonstrating robust anti-inflammatory efficacy. It induces phospholipase A2 inhibitory proteins (lipocortins), thereby strictly modulating the arachidonic acid cascade and downregulating the release of pro-inflammatory cytokines, leukotrienes, and prostaglandins without significant mineralocorticoid activity.
Moxifloxacin: An 8-methoxy advanced generation fluoroquinolone that optimally inhibits both Topoisomerase II and Topoisomerase IV. The methoxy group at the C-8 position minimizes the selection of resistant mutants and broadens coverage against atypical, Gram-positive, and Gram-negative organisms in ocular infections.
Indications
Treatment of bacterial conjunctivitis caused by susceptible organisms
Superficial ocular bacterial infections as advised by the treating ophthalmologist
Note: This is an indicative Indication, please follow the doctors advise. Do not self medicate.
Dosage & Administration
Instill 1 drop into the inferior conjunctival cul-de-sac of the affected eye(s) as prescribed by the physician. Dosing frequency should be adjusted according to clinical response and severity.
Note: This is an indicative dosage, please follow the doctors advise. Do not self medicate.
References
1. Korenfeld MS, et al. Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain. J Cataract Refract Surg. 2009;35(1):26-34.
2. Foster CS, et al. Efficacy and safety of difluprednate in endogenous anterior uveitis. Am J Ophthalmol. 2010;150(5):612-618.
1. Stroman DW, et al. In vitro and in vivo efficacy of moxifloxacin and gatifloxacin against ocular pathogens. Surv Ophthalmol. 2005;50 Suppl 1:S16-24.
Warning: This information is only for the use of registered medical practitioners only.
